Interestingly, resistance to TKIs can also cause lung adenocarcinoma to evolve into small-cell lung cancer (SCLC): roughly, 3% to 10% of EGFR-mutated NSCLC could shift to SCLC clinical subtype (44). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.